Nanoparticle imaging of integrins on tumor cells

Neoplasia

Volumn 8, Issue 3, 2006, Pages 214-222

  Montet, Xavier ^a   Montet Abou, Karin ^a   Reynolds, Fred ^a   Weissleder, Ralph ^a   Josephson, Lee ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Imaging; Integrin; Nanoparticle; Peptide; RGD

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; INTEGRIN; NANOPARTICLE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; FLUORESCENCE; HUMAN; HUMAN CELL; NANOTECHNOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMA HALF LIFE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; RAT; TUMOR CELL; TUMOR MODEL; TUMOR VASCULARIZATION;

EID: 33646350286     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.05769     Document Type: Article

References (56)

1. Ferrari M (2005). Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 5, 161-171.
2. NCI/NIH (2004). Cancer Nanotechnology Plan, A Strategic Initiative to Transform Clinical Oncology and Basic Research through Directed Application of Nanotechnology. (http://nano.cancer.gov/) Washington, DC, pp. 8-9.
3. Moghimi SM, Hunter AC, and Murray JC (2005). Nanomedicine: current status and future prospects. FASEB J 19, 311-330.
4. Reynolds F, O'Loughlin T, Weissleder R, and Josephson L (2005). Method of determining nanoparticle core weight. Anal Chem 77, 814-817.
5. Zhao M, Kircher MF, Josephson L, and Weissleder R (2002). Differential conjugation of tat peptide to superparamagnetic nanoparticles and its effect on cellular uptake. Bioconjug Chem 13, 840-844.
6. Schellenberger EA, Sosnovik D, Weissleder R, and Josephson L (2004). Magneto/optical annexin V, a multimodal protein. Bioconjug Chem 15, 1062-1067.
7. Kitov PI and Bundle DR (2003). On the nature of the multivalency effect: a thermodynamic model. J Am Chem Soc 125, 16271-16284.
8. Wright D and Usher L (2001). Multivalent binding in the design of bioactive compounds. Curr Org Chem 5, 1107-1131.
9. Mammen M, Chio S-K, and Whitesides GM (1998). Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Angew Chem Int Ed Engl 37, 2755-2794.
10. Munson PJ and Rodbard D (1979). Computer modeling of several ligands binding to multiple receptors. Endocrinology 105, 1377-1381.
11. Jain RK (1997). Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev 26, 71-90.
12. Jain RK (1990). Tumor physiology and antibody delivery. Front Radiat Ther Oncol 24, 32-46 (discussion, 64-68).
13. Winter PM, Morawski AM, Caruthers SD, Fuhrhop RW, Zhang H, Williams TA, Allen JS, Lacy EK, Robertson JD, Lanza GM, et al. (2003). Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation 108, 2270-2274.
14. Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, Xiang R, et al. (2002). Tumor regression by targeted gene delivery to the neovasculature. Science 296, 2404-2407.
15. Hallahan D, Geng L, Qu S, Scarfone C, Giorgio T, Donnelly E, et al. (2003). Integrin-mediated targeting of drug delivery to irradiated tumor blood vessels. Cancer Cell 3, 63-74.
16. Anderson SA, Rader RK, Westlin WF, Null C, Jackson D, Lanza GM, et al. (2000). Magnetic resonance contrast enhancement of neovasculature with alpha(v)beta(3)-targeted nanoparticles. Magn Reson Med 44, 433-439.
17. Arap W, Pasqualini R, and Ruoslahti E (1998). Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279, 377-380.
18. Yu X, Song SK, Chen J, Scott MJ, Fuhrhop RJ, Hall CS, et al. (2000). High-resolution MRI characterization of human thrombus using a novel fibrin-targeted paramagnetic nanoparticle contrast agent. Magn Reson Med 44, 867-872.
19. Schmieder AH, Winter PM, Caruthers SD, Harris TD, Williams TA, Allen JS, et al. (2005). Molecular MR imaging of melanoma angiogenesis with alpha(nu)beta(3)-targeted paramagnetic nanoparticles. Magn Reson Med 53, 621-627.
20. Kelly KA, Allport JR, Tsourkas A, Shinde-Patil VR, Josephson L, and Weissleder R (2005). Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle. Circ Res 96, 327-336.
21. Hall CS, Marsh JN, Scott MJ, Gaffney PJ, Wickline SA, and Lanza GM (2000). Time evolution of enhanced ultrasonic reflection using a fibrin-targeted nanoparticulate contrast agent. J Acoust Soc Am 108, 3049-3057.
22. Josephson L, Perez JM, and Weissleder R (2001). Magnetic nanosensors for the detection of oligonucleotide sequences. Angew Chem Int Ed Engl 40, 3204-3206.
23. Josephson L, Tung CH, Moore A, and Weissleder R (1999). High-efficiency intracellular magnetic labeling with novel superparamagnetic-Tat peptide conjugates. Bioconjug Chem 10, 186-191.
24. Koch AM, Reynolds F, Kircher MF, Merkle HP, Weissleder R, and Josephson L (2003). Uptake and metabolism of a dual fluorochrome Tat-nanoparticle in HeLa cells. Bioconjug Chem 14, 1115-1121.
25. Tsourkas A, Hofstetter O, Hofstetter H, Weissleder R, and Josephson L (2004). Magnetic relaxation switch immunosensors detect enantiomeric impurities. Angew Chem Int Ed Engl 43, 2395-2399.
26. Kelly KA, Reynolds F, Weissleder R, and Josephson L (2004). Fluorescein isothiocyanate-hapten immunoassay for determination of peptide-cell interactions. Anal Biochem 330, 181-185.
27. Mahmood U, Tung CH, Bogdanov A Jr, and Weissleder R (1999). Near-infrared optical imaging of protease activity for tumor detection. Radiology 213, 866-870.
28. Mahmood U, Tung CH, Tang Y, and Weissleder R (2002). Feasibility of in vivo multichannel optical imaging of gene expression: experimental study in mice. Radiology 224, 446-451.
29. Graves EE, Ripoll J, Weissleder R, and Ntziachristos V (2003). A submillimeter resolution fluorescence molecular imaging system for small animal imaging. Med Phys 30, 901-911.
30. Ntziachristos V and Weissleder R (2001). Experimental three-dimensional fluorescence reconstruction of diffuse media by use of a normalized Born approximation. Opt Lett 26, 893-895.
31. Ntziachristos V, Schellenberger EA, Ripoll J, Yessayan D, Graves E, Bogdanov A Jr, et al. (2004). Visualization of antitumor treatment by means of fluorescence molecular tomography with an annexin V-Cy5.5 conjugate. Proc Natl Acad Sci USA 101, 12294-12299.
32. Kuhn K and Eble J (1994). The structural bases of integrin-ligand interactions. Trends Cell Biol 4, 256-261.
33. Gurrath M, Muller G, Kessler H, Aumailley M, and Timpl R (1992). Conformation/activity studies of rationally designed potent anti-adhesive RGD peptides. Eur J Biochem 210, 911-921.
34. Aumailley M, Gurrath M, Muller G, Calvete J, Timpl R, and Kessler H (1991). Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett 291, 50-54.
35. 3 antagonists. J Am Chem Soc 118, 7461-7472.
36. Wunderbaldinger P, Josephson L, and Weissleder R (2002). Tat peptide directs enhanced clearance and hepatic permeability of magnetic nanoparticles. Bioconjug Chem 13, 264-268.
37. Brooks PC (1996). Role of integrins in angiogenesis. Eur J Cancer 32A, 2423-2429.
38. Stromblad S and Cheresh DA (1996). Cell adhesion and angiogenesis. Trends Cell Biol 6, 462-468.
39. Pasqualini R, Koivunen E, and Ruoslahti E (1997). Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol 15, 542-546.
40. Cheresh DA, Pytela R, Pierschbacher MD, Klier FG, Ruoslahti E, and Reisfeld RA (1987). An Arg-Gly-Asp-directed receptor on the surface of human melanoma cells exists in an divalent cation-dependent functional complex with the disialoganglioside GD2. J Cell Biol 105, 1163-1173.
41. Jonkmanns C, Saleh A, Rees M, and Moedder U (2002). Ultrasmall superparamagnetic iron oxide MRI of head and neck cancer: enhancement of primary tumor and influence on T staging. Radiology 225, 281 (Supplement).
42. Enochs WS, Harsh G, Hochberg F, and Weissleder R (1999). Improved delineation of human brain tumors on MR images using a long-circulating, superparamagnetic iron oxide agent. J Magn Reson Imaging 9, 228-232.
43. Varallyay P, Nesbit G, Muldoon LL, Nixon RR, Delashaw J, Cohen JI, et al. (2002). Comparison of two superparamagnetic viral-sized iron oxide particles ferumoxides and ferumoxtran-10 with a gadolinium chelate in imaging intracranial tumors. AJNR Am J Neuroradiol 23, 510-519.
44. Schmitz SA, Taupitz M, Wagner S, Wolf KJ, Beyersdorff D, and Hamm B (2001). Magnetic resonance imaging of atherosclerotic plaques using superparamagnetic iron oxide particles. J Magn Reson Imaging 14, 355-361.
45. Trivedi R, U-King-Im J, and Gillard J (2003). Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaque. Circulation 108, e140 (author reply, e140).
46. Saleh A, Schroeter M, Jonkmanns C, Hartung HP, Modder U, and Jander S (2004). In vivo MRI of brain inflammation in human ischaemic stroke. Brain 127, 1670-1677.
47. Lutz AM, Seemayer C, Corot C, Gay RE, Goepfert K, Michel BA, et al. (2004). Detection of synovial macrophages in an experimental rabbit model of antigen-induced arthritis: ultrasmall superparamagnetic iron oxide-enhanced MR imaging. Radiology 233, 149-157.
48. Politou P and Papanikolaou G (2004). Hepcidin: a key regulator involved in the pathogenesis of anemia of chronic disease. Haema 7, 165-174.
49. Weissleder R, Stark DD, Engelstad BL, Bacon BR, Compton CC, White DL, et al. (1989). Superparamagnetic iron oxide: pharmacokinetics and toxicity. AJR Am J Roentgenol 152, 167-173.
50. Kircher MF, Mahmood U, King RS, Weissleder R, and Josephson L (2003). A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. Cancer Res 63, 8122-8125.
51. Dechantsreiter MA, Planker E, Matha B, Lohof E, Holzemann G, Jonczyk A, et al. (1999). N-methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J Med Chem 42, 3033-3040.
52. Andronati SA, Karaseva TL, and Krysko AA (2004). Peptidomimetics-antagonists of the fibrinogen receptors: molecular design, structures, properties and therapeutic applications. Curr Med Chem 11, 1183-1211.
53. 3 integrin for a new cancer therapy. Angew Chem Int Ed Engl 36, 1374-1389.
54. Gao X, Cui Y, Levenson RM, Chung LW, and Nie S (2004). In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 22, 969-976.
55. Santra S, Liesenfeld B, Dutta D, Chatel D, Batich CD, Tan W, et al. (2005). Folate conjugated fluorescent silica nanoparticles for labeling neoplastic cells. J Nanosci Nanotechnol 5, 899-904.
56. Ow H, Larson DR, Srivastava M, Baird BA, Webb WW, and Wiesner U (2005). Bright and stable core-shell fluorescent silica nanoparticles. Nano Lett 5, 113-117.